글로벌 만성 안구 질환 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모                              

추산에 따르면, 전 세계 인구의 9% 이상이 65세 이상이며, 이 계층은 2050년까지 전 세계 인구의 약 17%를 차지할 것으로 예측됩니다. 연령 관련 황반변성, 백내장 , 당뇨망막병증, 녹내장과 같은 연령 관련 눈 문제는 미국에서 실명과 시력 손상의 가장 흔한 원인입니다. 약시와 사시는 두 가지 더 흔한 눈 질환입니다.

Data Bridge Market Research는 만성 안구 질환 시장이 2021년에 2,082만8,000달러 규모였으며 2029년까지 3,396만 달러에 도달할 것으로 예상되며 2022년부터 2029년까지의 예측 기간 동안 6.30%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

만성 안구 질환은 박테리아, 진균 및 알레르기 감염, 과도한 콘택트 렌즈 사용으로 인한 조직 건조, 눈과 눈 화장을 반복적으로 문지르는 것, 유전 및 대사 과정을 포함한 다양한 요인으로 인해 발생할 수 있습니다. 안구 질환이 있는 환자는 발적과 염증, 건조함, 흐릿한 시야, 붓기, 불편함 및 통증, 눈물 흘림 및 기타 증상을 경험할 수 있습니다.

만성 안구 질환 시장 동향

운전자

• 당뇨병 및 기타 만성 질환 의 높은 유병률

전 세계적으로 당뇨병 유병률이 증가함에 따라 시장 성장률이 확대되는 주요 원동력이 될 것입니다. 미국 안과 협회에 따르면 미국에는 진단되지 않은 당뇨병이 700만 명이 넘으며 매년 12,000~24,000명이 시력을 잃고 있습니다. 당뇨병성 망막증은 현재 미국에서 가장 흔한 실명 원인입니다. 당뇨병 환자는 매년 확장된 눈 검사를 받아야 합니다. 실명 및 기타 합병증과 같은 당뇨병 문제는 망막 이상을 주시함으로써 피할 수 있습니다. 이와 함께 백내장, 녹내장 및 연령 관련 황반변성과 같은 다양한 질병의 유병률은 시장 성장 요인으로 작용할 것입니다.

• 의료 인프라에 대한 투자 증가

Another significant factor influencing the growth rate of chronic eye diseases market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Increasing number of geriatric population

The increasing number of geriatric population is estimated to enhance the market’s growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. From 9.3 percent in 2020 to roughly 16.0 percent in 2050, the proportion of the population aged 65 and up is predicted to rise. The elderly population is expected to grow, and this group will need to be accommodated.

Furthermore, surging number of government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of chronic eye diseases market. Along with this, rising level of disposable income and growing government favourable initiatives will enhance the growth rate of the market.

Opportunities

• Rise in R&D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the chronic eye diseases market growth. New entrants are focusing on creating new steroid-based formulations to treat dry eye syndrome (DES), which is also a major driving element in the market. For instance, Kala Pharmaceuticals reported preliminary results from an additional clinical trial conducted to study the efficacy of its product Inveltys in temporarily relieving signs and symptoms of dry eye disease, and plans to resubmit the regulatory filing to the US Food and Drug Administration (USFDA) based on new data in March 2020.

Moreover, the market's growth is fueled by investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the chronic eye diseases market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of chronic eye diseases market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and strict drug approval mechanisms of testing bodies resulted in the delay of launch of new drugs will challenge the chronic eye diseases market. Additionally, lack of awareness among people and poor reimbursement policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This chronic eye diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic eye diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Chronic eye diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Chronic Eye Diseases Market

Since its emergence in December 2019, the COVID-19  virus had spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The chronic eye diseases market was negatively impacted by COVID-19. The sudden rise in coronavirus infections caused healthcare staff to focus on coronavirus management, obscuring other instances. There was a shortage of eye care drugs on the market due to restrictions on the flow of products and people. Furthermore, it resulted in a decrease in the number of individuals seeking treatment in hospitals and clinics. However, internet medical consultation and pharmaceutical sales have seen a surge in popularity. Following the COVID-19 relaxations, the market is quickly recovering.

Recent Development

• In January 2022, Sun Pharma had announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment which is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise the ocular tissue penetration.

Global Chronic Eye Diseases Market Scope

The chronic eye diseases market is segmented on the basis of type, medication, product type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Diabetic and Hypertensive Retinopathy
• Cataracts
• Age-Related Macular Degeneration (AMD)
• Thyroid Ophthalmopathy (Grave’s Disease)
• Glaucoma Dry Eye
• Others

Medication

• Anti-inflammatory
• Anti-glaucoma
• Lubricating Agents
• Immunosuppressive
• Others

Product Type

• Eye Drops
• Eye Ointment
• Gel
• Liquid Wipes
• Others

Route of Administration

• Oral
• Parenteral
• Ocular
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Chronic Eye Diseases Market Regional Analysis/Insights

The chronic eye diseases market is analysed and market size insights and trends are provided by country, type, medication, product type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the chronic eye diseases market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the chronic eye diseases market because of the growing prevalence of chronic eye syndrome and rising healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to growing number of patient population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Chronic Eye Diseases Market Share Analysis

The chronic eye diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chronic eye diseases market.

만성 안구 질환 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 엘리 릴리 앤드 컴퍼니(미국)
• 아스트라제네카(영국)
• 노바티스 AG(스위스)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 머크앤코(미국)
• 알러간(아일랜드)
• Bausch Health Companies Inc. (캐나다)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 사노피(프랑스)
• 머크 KGaA(독일)
• 오츠카 아메리카 제약 주식회사(미국)
• Akorn Operating Company LLC (미국)
• 알로스테라파마 주식회사(캐나다)
• I-Med Pharma Inc. (캐나다)
• 산텐제약 주식회사(일본)
• AFT Pharmaceuticals(뉴질랜드)
• Novaliq GmbH(독일)

SKU-53400